

Lei Zheng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9174599/publications.pdf>

Version: 2024-02-01

195
papers

11,481
citations

47409

49
h-index

39744

98
g-index

197
all docs

197
docs citations

197
times ranked

16752
citing authors

#	ARTICLE	IF	CITATIONS
1	Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 401-414.	0.7	11
2	Prognostic validity of the American joint committee on cancer eighth edition staging system for well-differentiated pancreatic neuroendocrine tumors. <i>Hpb</i> , 2022, 24, 681-690.	0.1	3
3	Giant obscurin regulates migration and metastasis via RhoA-dependent cytoskeletal remodeling in pancreatic cancer. <i>Cancer Letters</i> , 2022, 526, 155-167.	3.2	13
4	Upfront Chemotherapy Followed by Stereotactic Body Radiation Therapy with or without Surgery in Older Patients with Localized Pancreatic Cancer: A Single Institution Experience and Review of the Literature. <i>Current Oncology</i> , 2022, 29, 308-320.	0.9	2
5	High neutrophil-to-lymphocyte ratio following stereotactic body radiation therapy is associated with poor clinical outcomes in patients with borderline resectable and locally advanced pancreatic cancer. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 368-379.	0.6	6
6	Gemcitabine and XCT790, an ERK1/2 inverse agonist, display a synergistic anticancer effect in pancreatic cancer. <i>International Journal of Medical Sciences</i> , 2022, 19, 286-298.	1.1	6
7	Neoadjuvant and adjuvant antitumor vaccination alone or combination with PD1 blockade and CD137 agonism in patients with resectable pancreatic adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 558-558.	0.8	7
8	Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities. <i>Lancet Oncology</i> , The, 2022, 23, e62-e74.	5.1	36
9	Real-world clinical outcomes and molecular features of lung-specific and liver-specific metastases in pancreatic ductal adenocarcinoma (PDAC). <i>Journal of Clinical Oncology</i> , 2022, 40, 532-532.	0.8	0
10	Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity. <i>Annals of Surgical Oncology</i> , 2022, 29, 2456-2468.	0.7	12
11	High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi-agent chemotherapy. <i>Cancer Medicine</i> , 2022, , .	1.3	11
12	Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses. <i>Journal of Hematology and Oncology</i> , 2022, 15, 37.	6.9	23
13	Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled Trial. <i>Practical Radiation Oncology</i> , 2022, 12, 511-523.	1.1	5
14	Targeting MEN1-deficient tumors with DHODH inhibitor. <i>Journal of the National Cancer Center</i> , 2022, , .	3.0	0
15	CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	22
16	Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model. <i>Cancer Letters</i> , 2022, 539, 215722.	3.2	12
17	The Impact of the COVID-19 Pandemic on Multidisciplinary Clinics: A High-Volume Pancreatic Cancer Center Experience. <i>Current Problems in Diagnostic Radiology</i> , 2022, , .	0.6	1
18	RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. <i>JCO Precision Oncology</i> , 2022, , .	1.5	1

#	ARTICLE	IF	CITATIONS
19	Trial in progress: A randomized phase II study of pembrolizumab with or without defactinib, a focal adhesion kinase inhibitor, following chemotherapy as a neoadjuvant and adjuvant treatment for resectable pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2022, 40, TPS4192-TPS4192.	0.8	1
20	CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma. Cancer Letters, 2021, 499, 99-108.	3.2	22
21	Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. Cancer Letters, 2021, 497, 221-228.	3.2	10
22	Survival Outcomes of Adjuvant Chemotherapy Combined With Radiation Versus Chemotherapy Alone After Pancreatectomy for Distal Pancreatic Adenocarcinoma. Pancreas, 2021, 50, 64-70.	0.5	0
23	Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes. , 2021, 9, e001731.		45
24	A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint. Clinical Epigenetics, 2021, 13, 25.	1.8	11
25	Refining the Molecular Framework for Pancreatic Cancer with Single-cell and Spatial Technologies. Clinical Cancer Research, 2021, 27, 3825-3833.	3.2	8
26	Lipid and neutrophil accumulation and active inflammasome in high BMI tumor regions of human pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology, 2021, 39, e16271-e16271.	0.8	0
27	Novel strategies for immuno-oncology breakthroughs with cell therapy. Biomarker Research, 2021, 9, 62.	2.8	18
28	Drug-Coated Balloon versus Bare Nitinol Stent in Femoropopliteal Artery: 12 Months Outcome from a Single Center in China. Annals of Vascular Surgery, 2021, 74, 367-381.	0.4	1
29	ASO Visual Abstract: Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. Annals of Surgical Oncology, 2021, 28, 714-715.	0.7	1
30	Combination strategies to maximize the benefits of cancer immunotherapy. Journal of Hematology and Oncology, 2021, 14, 156.	6.9	202
31	New staging classification for pancreatic neuroendocrine neoplasms combining TNM stage and WHO grade classification []. Cancer Letters, 2021, 518, 207-213.	3.2	6
32	Long-term outcomes of a prospective single institution study with multiagent chemotherapy and stereotactic body radiation therapy in locally advanced or recurrent pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2021, 39, 440-440.	0.8	0
33	Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells. Cancer Biology and Medicine, 2021, 18, 206-214.	1.4	18
34	Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer. Annals of Surgery, 2021, 274, 162-169.	2.1	25
35	Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma. Clinical Cancer Research, 2021, 27, 1278-1286.	3.2	35
36	Pancreatic cancer cells render tumor-associated macrophages metabolically reprogrammed by a GARP and DNA methylation-mediated mechanism. Signal Transduction and Targeted Therapy, 2021, 6, 366.	7.1	37

#	ARTICLE	IF	CITATIONS
37	Cancer-associated fibroblast heterogeneity is associated with organ-specific metastasis in pancreatic ductal adenocarcinoma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 184.	6.9	26
38	Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. <i>OncolImmunology</i> , 2021, 10, 2001159.	2.1	10
39	Impact of somatic mutations on clinical and pathologic outcomes in borderline resectable and locally advanced pancreatic cancer treated with neoadjuvant chemotherapy and stereotactic body radiotherapy followed by surgical resection. <i>Radiation Oncology Journal</i> , 2021, 39, 304-314.	0.7	6
40	Vertebral body and splenic irradiation are associated with lymphopenia in localized pancreatic cancer treated with stereotactic body radiation therapy. <i>Radiation Oncology</i> , 2021, 16, 242.	1.2	7
41	Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. <i>British Journal of Cancer</i> , 2020, 122, 498-505.	2.9	105
42	A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. <i>Cancer Medicine</i> , 2020, 9, 1485-1494.	1.3	48
43	Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma. <i>Journal of the American College of Surgeons</i> , 2020, 231, 527-535.e14.	0.2	11
44	Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibitors in treating pancreatic cancer. , 2020, 8, e000351.		17
45	Nonselective β -adrenergic blockade impacts pancreatic cancer tumor biology, decreases perineural invasion and improves patient survival. <i>Annals of Pancreatic Cancer</i> , 2020, 3, 8-8.	1.2	0
46	A hemi-spleen injection model of liver metastasis for prostate cancer. <i>Prostate</i> , 2020, 80, 1263-1269.	1.2	7
47	Randomized Phase III Trial of Pegvorhialuronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3185-3194.	0.8	233
48	Epigenetics in modulating immune functions of stromal and immune cells in the tumor microenvironment. <i>Cellular and Molecular Immunology</i> , 2020, 17, 940-953.	4.8	41
49	Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2353-2362.	1.9	2
50	Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma. <i>Annals of Pancreatic Cancer</i> , 2020, 3, 7-7.	1.2	17
51	The tumour microenvironment in pancreatic cancer – clinical challenges and opportunities. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 527-540.	12.5	590
52	A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5129-5139.	3.2	67
53	Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis. <i>Clinical Cancer Research</i> , 2020, 26, 4842-4851.	3.2	72
54	Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 332-338.	0.5	140

#	ARTICLE	IF	CITATIONS
55	Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects. <i>Chronic Diseases and Translational Medicine</i> , 2020, 6, 6-17.	0.9	37
56	NF- κ B p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma. , 2020, 8, e000244.		7
57	Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2020, 13, 29.	6.9	146
58	Neoantigen-based EpiGVAX vaccine initiates antitumor immunity in colorectal cancer. <i>JCI Insight</i> , 2020, 5, .	2.3	22
59	HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhialuronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA).. <i>Journal of Clinical Oncology</i> , 2020, 38, 638-638.	0.8	51
60	An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma. <i>Oncotarget</i> , 2020, 11, 1929-1941.	0.8	7
61	In vivo bioluminescence tomography-guided radiation research platform for pancreatic cancer: an initial study using subcutaneous and orthotopic pancreatic tumor models. , 2020, 11224, .		4
62	Histomorphology of pancreatic cancer in patients with inherited ATM serine/threonine kinase pathogenic variants. <i>Modern Pathology</i> , 2019, 32, 1806-1813.	2.9	21
63	Axon Guidance Molecules Promote Perineural Invasion and Metastasis of Orthotopic Pancreatic Tumors in Mice. <i>Gastroenterology</i> , 2019, 157, 838-850.e6.	0.6	88
64	Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape. , 2019, 7, 224.		154
65	Strategies in Developing Immunotherapy for Pancreatic Cancer: Recognizing and Correcting Multiple Immune "Defects" in the Tumor Microenvironment. <i>Journal of Clinical Medicine</i> , 2019, 8, 1472.	1.0	56
66	Precision medicine in pancreatic cancer: treating every patient as an exception. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 805-810.	3.7	29
67	Determining the optimal number of examined lymph nodes for accurate staging of pancreatic cancer: An analysis using the nodal staging score model. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1069-1076.	0.5	17
68	Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4973-4984.	3.2	118
69	Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5351-5363.	3.2	57
70	Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies. , 2019, 7, 132.		46
71	Managing cardiotoxicity associated with immune checkpoint inhibitors. <i>Chronic Diseases and Translational Medicine</i> , 2019, 5, 6-14.	0.9	52
72	Signaling in the microenvironment of pancreatic cancer: Transmitting along the nerve. , 2019, 200, 126-134.		31

#	ARTICLE	IF	CITATIONS
73	From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. <i>Advances in Cancer Research</i> , 2019, 143, 63-144.	1.9	52
74	Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer. <i>Cancer Letters</i> , 2019, 452, 237-243.	3.2	78
75	A Direct Podocalyxin-Dynamin-2 Interaction Regulates Cytoskeletal Dynamics to Promote Migration and Metastasis in Pancreatic Cancer Cells. <i>Cancer Research</i> , 2019, 79, 2878-2891.	0.4	36
76	Extradomain-B Fibronectin-Targeted Dextran-Based Chemical Exchange Saturation Transfer Magnetic Resonance Imaging Probe for Detecting Pancreatic Cancer. <i>Bioconjugate Chemistry</i> , 2019, 30, 1425-1433.	1.8	25
77	Adding combination immunotherapy consisting of cancer vaccine, anti-PD-1 and anti-CSF1R antibodies to gemcitabine improves anti-tumor efficacy in murine model of pancreatic ductal adenocarcinoma. <i>Annals of Pancreatic Cancer</i> , 2019, 2, 21-21.	1.2	7
78	ZIP4 Promotes Muscle Wasting and Cachexia in Mice With Orthotopic Pancreatic Tumors by Stimulating RAB27B-Regulated Release of Extracellular Vesicles From Cancer Cells. <i>Gastroenterology</i> , 2019, 156, 722-734.e6.	0.6	82
79	Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 196-203.	1.9	61
80	Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 112-121.	0.9	54
81	E2F1 and E2F7 differentially regulate KPNA2 to promote the development of gallbladder cancer. <i>Oncogene</i> , 2019, 38, 1269-1281.	2.6	40
82	Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. <i>Annals of Surgery</i> , 2019, 270, 340-347.	2.1	280
83	IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma. <i>Journal of Clinical Investigation</i> , 2019, 129, 1742-1755.	3.9	47
84	Tumor mutational burden (TMB) and response rates to immune checkpoint inhibitors (ICIs) targeting PD-1, CTLA-4, and combination.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2578-2578.	0.8	3
85	A phase I open label study evaluating VT1021 in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS3158-TPS3158.	0.8	5
86	A phase II study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair-proficient (MMR-p) advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 563-563.	0.8	5
87	Epigenetic priming prior to pembrolizumab in mismatch repair-proficient advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 591-591.	0.8	6
88	Intrarenal delivery of bFGF-loaded liposome under guiding of ultrasound-targeted microbubble destruction prevent diabetic nephropathy through inhibition of inflammation. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2018, 46, 373-385.	1.9	20
89	ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism. <i>Clinical Cancer Research</i> , 2018, 24, 3186-3196.	3.2	59
90	Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?. <i>Annals of Surgery</i> , 2018, 268, 1-8.	2.1	139

#	ARTICLE	IF	CITATIONS
91	Vaccine Therapy and Immunotherapy for Pancreatic Cancer. , 2018, , 1461-1505.		0
92	Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy. Surgery, 2018, 163, 1090-1096.	1.0	35
93	Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Seminars in Arthritis and Rheumatism, 2018, 48, 553-557.	1.6	119
94	Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 100, 486-489.	0.4	2
95	Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and Effective. Annals of Surgical Oncology, 2018, 25, 280-289.	0.7	31
96	Immune defects in pancreatic cancer. Annals of Pancreatic Cancer, 2018, 1, 33-33.	1.2	5
97	Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. , 2018, 6, 118.		43
98	Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens. Journal of Immunology Research, 2018, 2018, 1-9.	0.9	75
99	HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. Journal of Clinical Oncology, 2018, 36, 359-366.	0.8	350
100	Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer. Cancers, 2018, 10, 39.	1.7	44
101	New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment. Biomedicines, 2018, 6, 87.	1.4	8
102	Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 2018, 267, 936-945.	2.1	425
103	Stereotactic body radiation therapy for palliative management of pancreatic adenocarcinoma in elderly and medically inoperable patients. Oncotarget, 2018, 9, 16427-16436.	0.8	28
104	Hedgehog signaling stimulates Tenascin C to promote invasion of pancreatic ductal adenocarcinoma cells through Annexin A2. Cell Adhesion and Migration, 2017, 11, 514-523.	1.1	9
105	MYBL2 is a Potential Prognostic Marker that Promotes Cell Proliferation in Gallbladder Cancer. Cellular Physiology and Biochemistry, 2017, 41, 2117-2131.	1.1	22
106	DNA methylation in the tumor microenvironment. Journal of Zhejiang University: Science B, 2017, 18, 365-372.	1.3	35
107	PD-L1 Expression in Pancreatic Cancer. Journal of the National Cancer Institute, 2017, 109, djw304.	3.0	43
108	Overcoming the resistance of pancreatic cancer to immune checkpoint inhibitors. Journal of Surgical Oncology, 2017, 116, 55-62.	0.8	46

#	ARTICLE	IF	CITATIONS
109	Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis. <i>Cell Reports</i> , 2017, 19, 203-217.	2.9	454
110	Current Standards of Chemotherapy for Pancreatic Cancer. <i>Clinical Therapeutics</i> , 2017, 39, 2125-2134.	1.1	80
111	Lnc <i>RNA</i> acts as a micro <i>RNA</i> sponge and promotes gallbladder tumorigenesis. <i>EMBO Reports</i> , 2017, 18, 1837-1853.	2.0	202
112	Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2399-2409.	1.9	27
113	Modified-FOLFIRINOX in metastatic pancreatic cancer: A prospective study in Chinese population. <i>Cancer Letters</i> , 2017, 406, 22-26.	3.2	47
114	Combination of coenzyme Q10-loaded liposomes with ultrasound targeted microbubbles destruction (UTMD) for early theranostics of diabetic nephropathy. <i>International Journal of Pharmaceutics</i> , 2017, 528, 664-674.	2.6	30
115	Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. <i>Cancer Medicine</i> , 2017, 6, 1552-1562.	1.3	19
116	Heterogeneous Stromal Signaling within the Tumor Microenvironment Controls the Metastasis of Pancreatic Cancer. <i>Cancer Research</i> , 2017, 77, 41-52.	0.4	71
117	Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems. <i>Journal of Clinical Oncology</i> , 2017, 35, 274-280.	0.8	124
118	Prevention of doxorubicin-induced cardiomyopathy using targeted MaFGF mediated by nanoparticles combined with ultrasound-targeted MB destruction. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 7103-7119.	3.3	27
119	Microfluidic device for primary tumor spheroid isolation. <i>Experimental Hematology and Oncology</i> , 2017, 6, 22.	2.0	24
120	Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 441-448.	0.6	4
121	Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. <i>Oncotarget</i> , 2017, 8, 44073-44081.	0.8	63
122	Stromal Annexin A2 expression is predictive of decreased survival in pancreatic cancer. <i>Oncotarget</i> , 2017, 8, 106405-106414.	0.8	14
123	Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma. <i>Chinese Clinical Oncology</i> , 2017, 6, 31-31.	0.4	12
124	Vaccine Therapy and Immunotherapy for Pancreatic Cancer. , 2017, , 1-45.		0
125	Preface: pancreas adenocarcinoma. <i>Chinese Clinical Oncology</i> , 2017, 6, 23-23.	0.4	0
126	Preface for Special Edition Pancreas Cancer. <i>Chinese Clinical Oncology</i> , 2017, 6, 57-57.	0.4	0

#	ARTICLE	IF	CITATIONS
127	Using basic fibroblast growth factor nanoliposome combined with ultrasound-introduced technology to early intervene the diabetic cardiomyopathy. <i>International Journal of Nanomedicine</i> , 2016, 11, 675.	3.3	11
128	Solitary splenic tuberculosis: a case report and review of the literature. <i>World Journal of Surgical Oncology</i> , 2016, 14, 154.	0.8	21
129	Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. <i>Annals of Surgery</i> , 2016, 264, 1073-1081.	2.1	131
130	Pancreatic cancer adjuvant radiotherapy target volume design: based on the postoperative local recurrence spatial location. <i>Radiation Oncology</i> , 2016, 11, 138.	1.2	11
131	Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer. <i>Practical Radiation Oncology</i> , 2016, 6, 417-424.	1.1	19
132	Cancer-Associated Fibroblasts in Pancreatic Cancer Are Reprogrammed by Tumor-Induced Alterations in Genomic DNA Methylation. <i>Cancer Research</i> , 2016, 76, 5395-5404.	0.4	95
133	Blocking NF- κ B Is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5939-5950.	3.2	39
134	Brain tumor-targeted delivery and therapy by focused ultrasound introduced doxorubicin-loaded cationic liposomes. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 269-280.	1.1	50
135	Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer. <i>Cancer Immunology Research</i> , 2016, 4, 225-233.	1.6	21
136	Current progress in immunotherapy for pancreatic cancer. <i>Cancer Letters</i> , 2016, 381, 244-251.	3.2	149
137	Prevent diabetic cardiomyopathy in diabetic rats by combined therapy of aFGF-loaded nanoparticles and ultrasound-targeted microbubble destruction technique. <i>Journal of Controlled Release</i> , 2016, 223, 11-21.	4.8	32
138	Interim results of a randomized phase II study of PEGPH20 added to nab-paclitaxel/gemcitabine in patients with stage IV previously untreated pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 439-439.	0.8	17
139	Identification of serologic biomarkers for predicting microvascular invasion in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 16362-16371.	0.8	21
140	Impact of stereotactic body radiation therapy on patient-reported quality of life in patients with unresectable or recurrent pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 413-413.	0.8	0
141	A prospective study evaluating stereotactic body radiation therapy in unresectable, recurrent, or residual pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 454-454.	0.8	0
142	Epigenetic priming prior to pembrolizumab in microsatellite-stable (MSS) advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS3626-TPS3626.	0.8	0
143	The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 259-265.	0.6	171
144	Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1805-1815.	1.9	36

#	ARTICLE	IF	CITATIONS
145	Interaction of Heat Shock Protein Cpn10 with the Cyclin E/Cdk2 Substrate Nuclear Protein Ataxia-Telangiectasia (NPAT) Is Involved in Regulating Histone Transcription. <i>Journal of Biological Chemistry</i> , 2015, 290, 29290-29300.	1.6	13
146	Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer. <i>Science Signaling</i> , 2015, 8, ra77.	1.6	89
147	Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. <i>Cancer</i> , 2015, 121, 1128-1137.	2.0	447
148	Small molecule drugs with immunomodulatory effects in cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2463-2468.	1.4	28
149	STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. <i>Science Translational Medicine</i> , 2015, 7, 283ra52.	5.8	543
150	Which patients with resectable pancreatic cancer truly benefit from oncological resection: is it destiny or biology?. <i>Cancer Biology and Therapy</i> , 2015, 16, 360-362.	1.5	8
151	The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience. <i>Annals of Surgical Oncology</i> , 2015, 22, 2352-2358.	0.7	147
152	PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors. <i>Journal of Immunotherapy</i> , 2015, 38, 1-11.	1.2	333
153	The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy. <i>Hpb</i> , 2015, 17, 292-298.	0.1	63
154	Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. <i>Oncimmunology</i> , 2015, 4, e1016700.	2.1	195
155	MicroRNA-320b promotes colorectal cancer proliferation and invasion by competing with its homologous microRNA-320a. <i>Cancer Letters</i> , 2015, 356, 669-675.	3.2	34
156	Resected pancreatic ductal adenocarcinomas with recurrence limited in lung have a significantly better prognosis than those with other recurrence patterns. <i>Oncotarget</i> , 2015, 6, 36903-36910.	0.8	62
157	TGF- β 2 blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner. <i>Oncotarget</i> , 2015, 6, 43005-43015.	0.8	68
158	Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 115-25.	0.6	22
159	Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors. <i>Cancer Biology and Medicine</i> , 2015, 12, 201-8.	1.4	67
160	The significance of ascites in patients with pancreatic cancer: A case-control study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 445-445.	0.8	1
161	Targeting Sema3D in pancreatic cancer: A novel therapeutic strategy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4129-4129.	0.8	1
162	Patient- versus physician-reported outcomes in patients enrolled in a prospective study involving stereotactic body radiation therapy in unresectable or recurrent pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 84-84.	0.8	8

#	ARTICLE	IF	CITATIONS
163	Stereotactic body radiation therapy and patient-reported quality of life prospectively evaluated in patients with unresectable or recurrent pancreatic cancer.. Journal of Clinical Oncology, 2015, 33, 92-92.	0.8	1
164	BEX1 Promotes Imatinib-Induced Apoptosis by Binding to and Antagonizing BCL-2. PLoS ONE, 2014, 9, e91782.	1.1	20
165	Does vaccine-primed pancreatic cancer offer better candidates for immune-based therapies?. Immunotherapy, 2014, 6, 1017-1020.	1.0	10
166	Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy. OncoImmunology, 2014, 3, e962401.	2.1	37
167	Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation. Cancer Immunology Research, 2014, 2, 616-631.	1.6	408
168	Specificity Delivers: Therapeutic Role of Tumor Antigen-Specific Antibodies in Pancreatic Cancer. Seminars in Oncology, 2014, 41, 559-575.	0.8	3
169	A Safety and Feasibility Study of an Allogeneic Colon Cancer Cell Vaccine Administered with a Granulocyte-Macrophage Colony Stimulating Factor-Producing Bystander Cell Line in Patients with Metastatic Colorectal Cancer. Annals of Surgical Oncology, 2014, 21, 3931-3937.	0.7	26
170	MicroRNA regulation network in colorectal cancer metastasis. World Journal of Biological Chemistry, 2014, 5, 301.	1.7	33
171	Pancreatic cancer stroma: Understanding biology leads to new therapeutic strategies. World Journal of Gastroenterology, 2014, 20, 2237.	1.4	105
172	A Preclinical Murine Model of Hepatic Metastases. Journal of Visualized Experiments, 2014, , 51677.	0.2	95
173	<scp>PAK1</scp> mediates pancreatic cancer cell migration and resistance to <scp>MET</scp> inhibition. Journal of Pathology, 2014, 234, 502-513.	2.1	44
174	Overcoming immune system evasion by personalized immunotherapy. Personalized Medicine, 2014, 11, 561-564.	0.8	1
175	Phase 2 study of programmed death-1 antibody (anti-PD-1, MK-3475) in patients with microsatellite unstable (MSI) tumors.. Journal of Clinical Oncology, 2014, 32, TPS3128-TPS3128.	0.8	4
176	A phase 2, multicenter study of FOLFIRINOX followed by ipilimumab in combination with allogeneic GM-CSF transfected pancreatic tumor vaccine in the treatment of metastatic pancreatic cancer.. Journal of Clinical Oncology, 2014, 32, TPS4160-TPS4160.	0.8	2
177	A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA).. Journal of Clinical Oncology, 2014, 32, 257-257.	0.8	36
178	Stereotactic body radiation therapy for pancreatic cancer: Single institutional experience.. Journal of Clinical Oncology, 2014, 32, 328-328.	0.8	4
179	Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas.. Journal of Clinical Oncology, 2014, 32, 269-269.	0.8	15
180	A phase 2 trial of low-dose multiagent chemotherapy with gemcitabine, docetaxel, capecitabine, and cisplatin (GTX-C) in subjects with metastatic pancreatic cancer.. Journal of Clinical Oncology, 2014, 32, 4135-4135.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Association of recurrence patterns following resection of pancreatic adenocarcinoma with overall survival.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4127-4127.	0.8	2
182	Role of Immune Cells and Immune-Based Therapies in Pancreatitis and Pancreatic Ductal Adenocarcinoma. <i>Gastroenterology</i> , 2013, 144, 1230-1240.	0.6	253
183	Multidisciplinary Management of Pancreatic Cancer. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 265-287.	0.6	29
184	Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relationships. <i>Journal of Radiation Oncology</i> , 2013, 2, 413-425.	0.7	74
185	Low Total Lymphocyte Count Is Associated with Poor Survival in Patients with Resected Pancreatic Adenocarcinoma Receiving a GM-CSF Secreting Pancreatic Tumor Vaccine. <i>Annals of Surgical Oncology</i> , 2013, 20, 725-730.	0.7	31
186	Integration of the metabolic/redox state, histone gene switching, DNA replication and S-phase progression by moonlighting metabolic enzymes. <i>Bioscience Reports</i> , 2013, 33, e00018.	1.1	36
187	Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer. <i>Journal of Immunotherapy</i> , 2013, 36, 382-389.	1.2	460
188	Vaccine therapy for pancreatic cancer. <i>Oncolmmunology</i> , 2013, 2, e26662.	2.1	50
189	Immunohistochemical Staining of B7-H1 (PD-L1) on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue. <i>Journal of Visualized Experiments</i> , 2013, , .	0.2	28
190	Exome Capture Sequencing of Adenoma Reveals Genetic Alterations in Multiple Cellular Pathways at the Early Stage of Colorectal Tumorigenesis. <i>PLoS ONE</i> , 2013, 8, e53310.	1.1	37
191	Prognostic factors for achieving resection following neoadjuvant radiation therapy for borderline resectable pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 285-285.	0.8	0
192	Is successful resection following neoadjuvant radiation therapy for borderline resectable pancreatic cancer dependent on improved tumor-vessel relationships?. <i>Journal of Clinical Oncology</i> , 2013, 31, 4057-4057.	0.8	1
193	Annexin A2 is a new antigenic target for pancreatic cancer immunotherapy. <i>Oncolmmunology</i> , 2012, 1, 112-114.	2.1	26
194	Vaccines for Pancreatic Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 642-652.	1.0	35
195	Tyrosine 23 Phosphorylation-Dependent Cell-Surface Localization of Annexin A2 Is Required for Invasion and Metastases of Pancreatic Cancer. <i>PLoS ONE</i> , 2011, 6, e19390.	1.1	152